EUSOBI 2026 - Med Pharma News

Graphic: IceCure ProSense breast cancer cryoablation, an ice ball around a tumour with the company-reported 97.5 percent 12-month response

IceCure ProSense Breast Cancer Cryoablation: Promising 12-Month Data Reported at EUSOBI 2026

Megan Wood4 hours ago4 hours ago010 mins

IceCure ProSense breast cancer cryoablation: the company reports 97.5% 12-month response in 40 patients. Study design and safety data were not disclosed.